Keryx Biopharmaceuticals (NASDAQ:KERX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.

Results 1 - 20 of 69 : 1 2 3 4 Next »

Recs

0
Member Avatar chitownatiiive (< 20) Submitted: 1/30/2014 8:08:49 PM : Outperform Start Price: $15.51 KERX Score: -18.51

i feel it. im brand at trying ive attempted to study the market but have been lazy this is a lucky guess based on how its already moving upward and is rated 80% bullish

Recs

1
Member Avatar zzlangerhans (99.73) Submitted: 6/14/2013 12:43:41 PM : Outperform Start Price: $7.03 KERX Score: +77.95

Now that the GSK takeout rumor has been put to rest, the debate on Zerenex can return to the more rational concerns over IP protection and commercial viability against generic competition. These are certainly valid concerns but I believe they will be muted once the Zerenex NDA and MAA are submitted next quarter, only to resurface with a vengeance after likely FDA and EMA approval.

Recs

0
Member Avatar Litigation (26.10) Submitted: 3/16/2013 7:15:33 PM : Outperform Start Price: $7.25 KERX Score: +64.89

Price Target: $13

Recs

0
Member Avatar scrubs62074 (88.85) Submitted: 1/23/2013 2:03:57 PM : Outperform Start Price: $3.81 KERX Score: +228.42

High volume breakout 1/23/13

Recs

0
Member Avatar NHWeston102 (81.52) Submitted: 7/6/2012 10:13:26 PM : Outperform Start Price: $1.93 KERX Score: +559.73

Outclassed in all its categories but a fair buy-out candidates.

Recs

0
Member Avatar Robase06 (< 20) Submitted: 5/23/2012 10:12:36 PM : Outperform Start Price: $1.78 KERX Score: +615.65

Zerenex

Recs

0
Member Avatar TXKL (< 20) Submitted: 5/16/2012 4:05:00 PM : Outperform Start Price: $1.85 KERX Score: +587.28

Big buyout rumors.

Recs

0
Member Avatar someboy0808 (< 20) Submitted: 5/11/2012 6:47:34 PM : Outperform Start Price: $1.98 KERX Score: +541.02

Top line Positive phase 3 drug report from Japan, and 100million license fee, you know this company is not going down any time soon!

Recs

0
Member Avatar wcaddict (< 20) Submitted: 4/23/2012 12:10:52 PM : Outperform Start Price: $1.71 KERX Score: +650.93

news

Recs

0
Member Avatar Stef100000 (< 20) Submitted: 4/10/2012 1:22:13 PM : Underperform Start Price: $1.42 KERX Score: -811.02

No future

Recs

0
Member Avatar solanZRaider (< 20) Submitted: 4/2/2012 5:36:17 PM : Outperform Start Price: $1.69 KERX Score: +664.86

bravo

Recs

0
Member Avatar WRXkid (77.10) Submitted: 3/29/2012 2:01:49 PM : Outperform Start Price: $4.83 KERX Score: +145.03

Possible positive outcome of clinical trials for perifosine.

Recs

0
Member Avatar saulucy20 (< 20) Submitted: 3/16/2012 6:02:54 AM : Outperform Start Price: $4.18 KERX Score: +189.22

Phase 3 on Perifosine

Recs

0
Member Avatar RBuskey106 (63.41) Submitted: 3/14/2012 10:42:20 PM : Outperform Start Price: $4.10 KERX Score: +195.27

Betting on perifosine for the short term bump

Recs

0
Member Avatar KimLanners (< 20) Submitted: 10/14/2011 1:51:20 PM : Outperform Start Price: $2.79 KERX Score: +329.54

biotech

Recs

0
Member Avatar vaderblue (59.99) Submitted: 8/31/2011 5:00:26 PM : Outperform Start Price: $4.11 KERX Score: +175.08

I am an investor of Kerx for along time. I am hinting this is a must deal for them. Good news today but like
having babies, we must wait it out.

Recs

0
Member Avatar bikesncats (28.76) Submitted: 7/15/2011 4:25:23 AM : Outperform Start Price: $4.92 KERX Score: +132.01

Phase 3 trials will show if this "lottery ticket" has what is takes to become a 10 bagger, I believe so.

Recs

0
Member Avatar almostgem (30.16) Submitted: 6/9/2011 2:51:10 PM : Outperform Start Price: $4.83 KERX Score: +135.17

See Aezs - This company has exclusive rights to market a cancer drug that is now in stage III trials. If successful, both companies should soar !

Recs

0
Member Avatar yazzbro (20.52) Submitted: 5/16/2011 3:10:22 PM : Outperform Start Price: $4.90 KERX Score: +135.15

They have a nice looking pipeline with some pretty good look potential. I think it is a bit on the risky side but, with great risk comes great reward.

Recs

0
Member Avatar ClovisMeinhardt1 (< 20) Submitted: 5/6/2011 4:50:51 PM : Outperform Start Price: $4.72 KERX Score: +146.27

Anything to do with the diabetic epidemic should perform well, as long as management does their job and stays focussed.

Results 1 - 20 of 69 : 1 2 3 4 Next »

Featured Broker Partners


Advertisement